This didactic conference will educate scientists on the processes of translating basic research into novel therapies and will leave participants with a strong knowledge base and relevant resources to address the associated barriers and challenges in developing a drug.

The programs will also highlight case studies of small molecule and biologics programs at different stages of development aimed at tackling challenging CNS targets relevant to neurodegenerative diseases.
 

WHAT WILL YOU LEARN?

1. Challenges and opportunities in academic drug discovery
2. Fundamentals of medicinal chemistry relevant to drug discovery for neurodegenerative diseases
3. Newest trends in assay development and high throughput screening (HTS)
4. Go-no-go criteria for preclinical development, including pharmacokinetic behavior of candidate compounds, aqueous solubility, blood-brain barrier permeability, preliminary safety, and manufacturing issues
5. Study design considerations for animal model experiments
6. Biologics for challenging CNS targets and strategies to optimize brain delivery
7. Requirements for an Investigational New Drug (IND) application
8. Commercialization strategies for developing science into products
9. Best practices for working with tech transfer offices, managing intellectual property, and the role of funding organizations
10. Funding & resources for preclinical therapeutics development for neurological disorders